DYSLIPIDEMIA: THE ROLE OF HEREDITARY AND SECONDARY FACTORS

Authors

  • Ibragimov Muboshsher Muzaffar ugli Central Asian Medical University, clinical resident in Cardiology, Fergana, Republic of Uzbekistan Author
  • Rakhmonov Kamoldin Khaydarovich Doctor of Medical Sciences (DSc), Director of the Fergana Branch of the Republican Specialized Scientific and Practical Medical Center of Cardiology, Fergana, Republic of Uzbekistan Author

Keywords:

dyslipidemia, familial hypercholesterolemia, familial chylomicronemia syndrome, secondary dyslipidemia, hypothyroidism, type 2 diabetes mellitus, chronic kidney disease, metabolic dysfunction-associated fatty liver disease, cardiovascular risk.

Abstract

 The review analyzes current evidence on the role of hereditary and secondary factors in the development of dyslipidemia. Publications were searched in PubMed and Google Scholar for 2021–2025. The epidemiology of dyslipidemia in different populations, the D.S. Fredrickson classification, the genetic basis of familial chylomicronemia syndrome and familial hypercholesterolemia, as well as the features of lipid metabolism disorders in hypothyroidism, type 2 diabetes mellitus, chronic kidney disease, liver diseases and drug exposure are discussed. Familial dyslipidemias, despite their low prevalence, have a high atherogenic potential and require combined lipid-lowering therapy, whereas secondary dyslipidemias are far more common, and their correction should be combined with treatment of the underlying disease or withdrawal of the causative drug. Timely identification of the etiological factor of dyslipidemia allows personalized prevention of cardiovascular diseases.

References

1.Li Z., Zhu G., Chen G. et al. Distribution of lipid levels and prevalence of hyperlipidemia: data from the NHANES 2007–2018 // Lipids Health Dis. – 2022. – Vol. 21, № 1. – P. 111. DOI: 10.1186/s12944-022-01721-y

2.Lu Y., Zhang H., Lu J. et al. Prevalence of dyslipidemia and availability of lipid-lowering medications among primary health care settings in China // JAMA Netw Open. – 2021. – Vol. 4, № 9. – e2127573. DOI: 10.1001/jamanetworkopen.2021.27573

3.Islam M.T., Samad Talha M.T.U., Shafiq S.S. et al. Prevalence, pattern, and correlates of dyslipidemia in Bangladeshi individuals // J Clin Lipidol. – 2023. – Vol. 17, № 6. – P. 788–799. DOI: 10.1016/j.jacl.2023.09.007

4.Вилков В.Г., Шальнова С.А. Тридцатилетняя динамика распространённости кардиометаболических факторов риска в популяциях Российской Федерации и Соединённых Штатов Америки // Кардиоваскулярная терапия и профилактика. – 2022. – Т. 21, № 8. – С. 34–39. DOI: 10.15829/1728-8800-2022-3304

5.Andrades C.D.S., Poletti V.V., Closs V.E. et al. Prevalence of dyslipidemia, atherogenic and cardiovascular risk in overweight and obese adolescents // Rev Paul Pediatr. – 2023. – Vol. 41. – e2021312. DOI: 10.1590/1984-0462/2023/41/2021312

6.Драпкина О.М., Имаева А.Э., Куценко В.А. и др. Дислипидемии в Российской Федерации: популяционные данные, ассоциации с факторами риска // Кардиоваскулярная терапия и профилактика. – 2023. – Т. 22, № 8S. – С. 92–104. DOI: 10.15829/1728-8800-2023-3791

7.Huang J.X.F., Yousaf A., Moon J. et al. Recent advances in the management of dyslipidemia: a systematic review // Cureus. – 2025. – Vol. 17, № 3. – e81034. DOI: 10.7759/cureus.81034

8.Mainieri F., La Bella S., Chiarelli F. Hyperlipidemia and cardiovascular risk in children and adolescents // Biomedicines. – 2023. – Vol. 11. – P. 809. DOI: 10.3390/biomedicines11030809

9.Regmi M., Rehman A. Familial hyperchylomicronemia syndrome // StatPearls [Internet]. – Treasure Island (FL): StatPearls Publishing, 2025.

10.Nohara A., Tada H., Ogura M. et al. Homozygous familial hypercholesterolemia // J Atheroscler Thromb. – 2021. – Vol. 28, № 7. – P. 665–678. DOI: 10.5551/jat.RV17050

11.Blom D.J., Marais A.D., Raal F.J. Homozygous familial hypercholesterolemia treatment: new developments // Curr Atheroscler Rep. – 2025. – Vol. 27, № 1. – P. 22. DOI: 10.1007/s11883-024-01269-5

12.Santos R.D., Wiegman A., Caprio S. et al. Alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: a randomized clinical trial // JAMA Pediatr. – 2024. – Vol. 178, № 3. – P. 283–293. DOI: 10.1001/jamapediatrics.2023.6477

13.Tada H., Harada-Shiba M. Assessments of atherosclerosis and treatment strategies for heterozygous familial hypercholesterolemia // J Atheroscler Thromb. – 2025. – Vol. 32, № 10. – P. 1211–1219. DOI: 10.5551/jat.RV22041

14.Liu H., Peng D. Update on dyslipidemia in hypothyroidism: the mechanism of dyslipidemia in hypothyroidism // Endocr Connect. – 2022. – Vol. 11, № 2. – e210002. DOI: 10.1530/EC-21-0002

15.Su X., Chen X., Peng H. et al. Novel insights into the pathological development of dyslipidemia in patients with hypothyroidism // Bosn J Basic Med Sci. – 2022. – Vol. 22, № 3. – P. 326–339. DOI: 10.17305/bjbms.2021.6606

16.Martin S.S., Daya N., Lutsey P.L. et al. Thyroid function, cardiovascular risk factors, and incident atherosclerotic cardiovascular disease: the Atherosclerosis Risk in Communities (ARIC) study // J Clin Endocrinol Metab. – 2017. – Vol. 102, № 9. – P. 3306–3315. DOI: 10.1210/jc.2017-00986

17.Luxia L., Jingfang L., Songbo F. et al. Correlation between serum TSH levels within normal range and serum lipid profile // Horm Metab Res. – 2021. – Vol. 53, № 1. – P. 32–40. DOI: 10.1055/a-1191-7953

18.Gao M., Cao L., Wang H. et al. Correlation between subclinical hypothyroidism and dyslipidemia in women in northeast China // Acta Endocrinol (Buchar). – 2021. – Vol. 17, № 2. – P. 282–285. DOI: 10.4183/aeb.2021.282

19.Van Vliet N.A., Bos M.M., Thesing C.S. et al. Higher thyrotropin leads to unfavorable lipid profile and somewhat higher cardiovascular disease risk: evidence from multi-cohort Mendelian randomization and metabolomic profiling // BMC Med. – 2021. – Vol. 19, № 1. – P. 266. DOI: 10.1186/s12916-021-02130-1

20.Kane J.P., Pullinger C.R., Goldfine I.D. et al. Dyslipidemia and diabetes mellitus: role of lipoprotein species and interrelated pathways of lipid metabolism in diabetes mellitus // Curr Opin Pharmacol. – 2021. – Vol. 61. – P. 21–27. DOI: 10.1016/j.coph.2021.08.013

21.Kalra S., Raizada N. Dyslipidemia in diabetes // Indian Heart J. – 2024. – Vol. 76, Suppl. 1. – P. S80–S82. DOI: 10.1016/j.ihj.2023.11.002

22.Karakasis P., Theofilis P., Patoulias D. et al. Diabetes-driven atherosclerosis: updated mechanistic insights and novel therapeutic strategies // Int J Mol Sci. – 2025. – Vol. 26, № 5. – P. 2196. DOI: 10.3390/ijms26052196

23.Liu J., Kang J., Liang P. et al. The association between triglyceride-glucose index and all-cause/cardiovascular mortality in patients with different glucose metabolism statuses // Cardiovasc Diabetol. – 2025. – Vol. 24, № 1. – P. 367. DOI: 10.1186/s12933-025-02826-1

24.Ikeda I., Igarashi R., Fujihara K. et al. Cross-sectional and longitudinal associations between family history of type 2 diabetes mellitus, hypertension, and dyslipidemia and their prevalence and incidence: Toranomon Hospital Health Management Center Study (TOPICS24) // Mayo Clin Proc. – 2025. – Vol. 100, № 8. – P. 1370–1382. DOI: 10.1016/j.mayocp.2024.10.020

25.Kim J.Y., Chung S.M., Kim N.H. Managing dyslipidemia in chronic kidney disease: a comprehensive overview of evidence and recommendations // Korean J Intern Med. – 2025. – Vol. 40, № 6. – P. 876–889. DOI: 10.3904/kjim.2025.099

Downloads

Published

2026-09-26